Literature DB >> 1967629

Use of microdialysis for monitoring tyrosine hydroxylase activity in the brain of conscious rats.

B H Westerink1, J B De Vries, R Duran.   

Abstract

An on-line microdialysis system was developed which monitored the 3,4-dihydroxyphenylalanine (DOPA) formation in the striatum during infusion of a submicromolar concentration of an L-aromatic amino-acid decarboxylase inhibitor (NSD 1015). The absence of DOPA in dialysates of 6-hydroxydopamine-pretreated rats and the disappearance of DOPA after administration of alpha-methyl-p-tyrosine indicated that the dialyzed DOPA was derived from dopaminergic nerve terminals. Next we investigated whether the steady-state DOPA concentration in striatal dialysates could be considered as an index of tyrosine hydroxylase activity. The increase in DOPA output after intraperitoneal administration of haloperidol or gamma-butyrolactone and the decrease in DOPA output after intraperitoneal administration of apomorphine are in excellent agreement with results of postmortem studies, in which a decarboxylase inhibitor was used to measure the activity of tyrosine hydroxylase. The effect of haloperidol on DOPA formation was not visible when a U-shaped cannula (0.80 mm o.d.) was used. Some methodological problems related to microdialysis of the haloperidol-induced increase in DOPA formation are discussed. We concluded that the proposed model is a powerful and reliable in vivo method to monitor tyrosine hydroxylase activity in the brain. The method is of special interest for investigating the effect of compounds which are not able to pass the blood-brain barrier. As an application of the method in the latter situation, we report the effect of infusion the neurotoxin 1-methyl-4-phenylpyridinium ion (10 mmol/L infused over 20 min) on the activity of striatal tyrosine hydroxylase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967629     DOI: 10.1111/j.1471-4159.1990.tb01884.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.

Authors:  C Bencsics; S R Wachtel; S Milstien; K Hatakeyama; J B Becker; U J Kang
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

2.  Effects of manganese on extracellular levels of dopamine in rat striatum: an analysis in vivo by brain microdialysis.

Authors:  L Vidal; M Alfonso; F Campos; L R F Faro; R C Cervantes; R Durán
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

3.  Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis.

Authors:  H Hashiguti; D Nakahara; W Maruyama; M Naoi; T Ikeda
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.

Authors:  S Sarre; P Herregodts; D Deleu; A Devrieze; N De Klippel; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

5.  Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.

Authors:  M J During; J R Naegele; K L O'Malley; A I Geller
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

6.  In vivo evidence for a concordant response of terminal and dendritic dopamine release during intranigral infusion of drugs.

Authors:  B H Westerink; M Santiago; J B De Vries
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-12       Impact factor: 3.000

7.  L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat.

Authors:  Zachary D Brodnik; Manda Double; Rodrigo A España; George E Jaskiw
Journal:  Neuropharmacology       Date:  2017-05-29       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.